Fig. 5.

CUDC-907 enhances ADCC of mAbs by upregulating MICA, ULBp-2/5/6, CD38 while downregulating c-Myc. a Histograms show MICA/B, ULBp-2/5/6, and CD38 expression in RPMI8226 and U266 cells treated with 10 nM CUDC-907. b Summary of the ratio of MFI for MICA/B, ULBp-2/5/6, and CD38 expression in cells exposed to CUDC-907. The MFI values of MICA/B, ULBp-2/5/6, and CD38 of MM cells upon exposure to CUDC-907 were divided by the corresponding MFI values upon exposure to DMSO. Experiments were repeated 5 times. Error bars represent the SD. (*p < 0.05, **p < 0.01, “ns” indicates no significant difference). c-f MICA, IKZF1/3, Myc mRNA levels in RPMI8226 cells exposed to CUDC-907. Experiments were performed in triplicate (n = 3). (*p < 0.05, **p < 0.01, “ns” indicates no significant difference). g–h ADCC assay of daratumumab and elotuzumab. Experiments were performed in triplicate (n = 3), and data are presented as the mean ± SD. P-values were calculated for the interaction terms in the regression models, which are interpreted as the difference in slope of dose-dependent change between the groups (**p < 0.01). i Western blot validation of the effects of CUDC-907 on RPMI8226 cells